Australia discovers and trials, then sells before the value arrives. The gap is not science or talent but the few hundred million dollars a phase three trial costs – and who is willing to fund it.
Startup · Topic
Healthcare & Biotech
Expert guides, analysis and tool comparisons on Healthcare & Biotech from the kurums.com Startup desk — written for business decision-makers and updated as the market moves.
- 5 guides
- Updated Aug 1, 2026
Latest in Healthcare & Biotech
How Australia Decides What Medicines Cost
A medicine can be approved as safe and effective in Australia and still be unavailable, because a second committee decides whether it is worth the money. How PBS cost-effectiveness assessment works.
Australian Pathology: A Medical Business That Runs on Logistics
A pathology lab processes each extra sample for almost nothing, so volume decides everything. Why the sector consolidated, why collection centre location is contested, and why Medicare sets the price.
Cochlear and ResMed: Why the Device Sale Is Not the Business
A Cochlear implant creates a customer for seventy years. A ResMed device creates a consumables relationship for decades. Why both Australian device companies are annuities rather than manufacturers.
CSL: How a 1916 Government Laboratory Became a Global Plasma Giant
CSL was created in 1916 because Australia was too isolated to import vaccines. It is now a US$15.5 billion plasma therapeutics company – and its moat is a collection network, not a molecule.
All guides
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.